Healthcare Private Placement and M&A Transactions Review Week Ending September 22, 2024

Nura Bio: The company raised $141 million of Series A venture funding in a deal led by The Column Group on September 17, 2024, putting the company’s pre-money valuation at $35 million. Sanofi Ventures, Samsara BioCapital, Euclidean Capital, and other undisclosed investors also participated in the round. The company is a developer of transformative neuroprotective therapies designed to prevent and protect against neuronal loss related to neuroimmune dysregulation.

Neo Medical: The company received $68 million of development capital from Gyrus Capital, Mr. Jonas Larsson, Mr. Vincent Lefauconnier and undisclosed existing investors on September 17, 2024. The company is a developer of spinal surgery instruments designed to offer patient-specific spinal care.

GC Therapeutics: The company raised $65 million of Series A venture funding in a deal led by Mubadala Investment Company and Cormorant Asset Management on September 19, 2024. Cercano Management, Pear (California), Andreessen Horowitz, Medical Excellence Capital, Calm Ventures and Gaingels also participated in the round. The company is an operator of a genome-wide cell landscape exploration company intended to program patient-derived stem cells into any cell type.

ONL Therapeutics: The company raised $65 million of Series D venture funding in a deal led by Johnson & Johnson Innovation – JJDC on September 16, 2024. Novartis, Bios Partners, Visionary Ventures and other undisclosed investors also participated in the round. The company is an operator of a clinical-stage biopharmaceutical business committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease.

RejuvenAir: The company raised $53 million of Series D venture funding in a deal led by Yonjin Venture and TVM Capital Life Science on September 18, 2024. Ascension Ventures, Intersouth Partners, SV Health Investors, First Analysis and Blue Heron Ventures also participated in the round. The company is a developer of an interventional device designed to offer the therapy of chronic obstructive pulmonary disease with chronic bronchitis using metered cryospray.

Nomic: The company raised $42 million of Series B venture funding from Avant Bio, Real Ventures and Lux Capital on September 17, 2024. SR One Capital Management, Amplitude Ventures, and other undisclosed investors also participated in the round. The company is a developer of a bioengineering business focused on providing protein profiling services.

Brenus Pharma: The company raised EUR 22.2 million of Series A venture funding in a deal led by Angelor on September 18, 2024. Crédit Agricole Centre France Développement, UI Investissement and Crédit Agricole Centre Ouest also participated in the round. The company is a developer of anti-cancer cell-based immunotherapy designed to generate allogeneic cell vaccines to combat solid tumors.

Neuro42: The company raised $22.2 million of venture funding from Zynext Ventures and Karna D Shinde on September 16, 2024. The company is a developer of portable magnetic resonance imaging machines designed to offer diagnosis and interventions for neurological conditions.

Syntax Bio: The company raised $15 million of Series A venture funding from Astellas Venture Management, Illumina Ventures and EGB Capital on September 18, 2024. Portal Innovations, DCVC Bio and Civilization Ventures also participated in the round. The company is an operator of a genetic programming cell therapy platform.

Ferrum Health: The company raised $16 million of Series A venture funding in a deal led by Foundry Group on September 19, 2024, putting the company’s pre-money valuation at $28.5 million. Singtel Innov8, Catalyst by Wellstar, Cercano Management, Urban Innovation Fund, GSR Ventures China, Blumberg Capital, Headwater Ventures and United Healthcare Accelerator also participated in the round. The company is a developer of an artificial intelligence monitoring technology designed to reduce medical errors and improve patient outcome.

Luminate Medical: The company raised $15 million of Series A venture funding in a deal led by ARTIS Ventures on September 18, 2024. SciFounders, Faber Ventures, Metaplanet Holdings, 8VC, Lachy Groom, and other undisclosed investors also participated in the round. The company is a developer of a novel device designed to prevent hair loss during chemotherapy.

ImmunOs Therapeutics: The company raised $11 million of Series C venture funding in a deal led by BioMedPartners, Pfizer Ventures, Gimv and Mission BioCapital on September 17, 2024. Double Point Ventures and other undisclosed investors also participated in the round. The company is a developer of novel human immunomodulatory proteins and drugs designed to treat cancer and autoimmune diseases.

Curadel Pharma: The company raised $7.5 million of venture funding from undisclosed investors on September 18, 2024. The company is a research and development business specializing in novel devices and drugs for the treatment of cancer and other diseases.

Starling Medical: The company raised $6.75 million of venture funding from undisclosed investors on September 18, 2024. The company is a developer of a healthcare device designed for continuous monitoring and early detection of health issues based on urine analysis.
CuraSen: The company raised $5.8 million of Series B venture funding from undisclosed investors on September 18, 2024, putting the company’s pre-money valuation at $117.7 million. The company is an operator of a biopharmaceutical business intended for the development of novel treatments for neurodegenerative diseases.

Novostia: The company raised CHF 5.6 million of venture funding from undisclosed investors on September 17, 2024. The company is an operator of a medical device business intended to develop an innovative artificial heart valve for patients of any age, including children.

Alesi Surgical: The company raised GBP 5 million of venture funding in a deal led by Mercia Asset Management on September 19, 2024. IP Group, Panakes Partners and other undisclosed investors also participated in the round. The company is a developer of laparoscopic surgical tools designed to improve the safety, efficiency, and outcomes of advanced surgical procedures.

Reactive Robotics: The company raised EUR 5 million of venture funding from The TQ Group, Dr. Doll Holding and Henrik Schunk Beteiligungen on September 16, 2024. European Innovation Council Fund and Stephan Huber also participated in the round. The company is a developer of an artificial intelligence-driven robot intended to assist in early mobilization of ICU patients.

VerImmune: The company raised $4.5 million of venture funding in a deal led by Bailey Biofund on September 22, 2024. Proxima Ventures, Gaingels, Mana Ventures, John Ballantyne, and other undisclosed investors also participated in the round. The company is a developer of biotechnology immuno-medicines designed to provide cancer therapy known as anti-tumor immune redirection.

DeepLook Medical: The company raised an undisclosed amount of Series A venture funding in a deal led by Xcellerant Ventures on September 19, 2024. OKG Capital and Citrine Angels also participated in the round. The company is a developer of a medical imaging platform designed to improve the detection of early breast cancer in mammograms.

Silk Road Medical / Boston Scientific: The company was acquired by Boston Scientific for $1.26 billion on September 17, 2024. Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke through combining surgical principles of neuroprotection with invasive endovascular techniques to treat blockages in the carotid artery.

Dermavant Sciences / Organon & Co.: The company reached a definitive agreement to be acquired by Organon & Co., a subsidiary of Merck & Co., for an undisclosed amount on September 18, 2024. Dermavant Science Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics in medical dermatology.

Integrated Oncology Network / Cardinal Health: The company reached a definitive agreement to be acquired by Cardinal Health for up to $1.2 billion on September 20, 2024. The company is a provider of oncology center development, management, and advisory services, and capital for physician practices and hospitals.

Alimera Sciences / ANI Pharmaceuticals: The company was acquired by ANI Pharmaceuticals for $381 million on September 16, 2024. Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema, a cause of blindness, and non-infectious uveitis affecting the posterior segment of the eye.

G1 Therapeutics / Pharmacosmos: The company was acquired by Pharmacosmos for $282.3 million on September 18, 2024. G1 Therapeutics Inc is a commercial-stage biopharmaceutical company engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer.

RLS Radiopharmacies / Telix Pharmaceuticals: The company, a subsidiary of RLS Group, reached a definitive agreement to be acquired by Telix Pharmaceuticals for $250 million on September 22, 2024. The company is an operator of a radiopharmacy network intended to offer safe and reliable access to life-saving radiopharmaceuticals.

OmniLife Health / Xvivo Group: The company reached a definitive agreement to be acquired by Xvivo Group for $7 million on September 18, 2024. The company is a developer of a clinical workflow automation platform dedicated to helping clinicians and patients achieve optimal health outcomes with purpose-built tools that simplify complex care pathways.

Care.ai / Stryker: The company was acquired by Stryker for an undisclosed amount on September 17, 2024. The company is a developer of an AI-powered sensor-based ambient monitoring technology designed to support care teams.

Longevity Biomedical / FutureTech II Acquisition: The company reached a definitive agreement to acquire FutureTech II Acquisition through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol LBIO on September 16, 2024. Longevity Biomedical Inc is a clinical-stage biomedical company focused on advancing technologies across therapeutics, health monitoring and digital health solutions to restore tissue form and function in order to increase and improve health span.

Nico / Stryker: The company was acquired by Stryker for an undisclosed amount on September 20, 2024. The company is a developer of minimally invasive surgical devices designed to be used in neurosurgery.

SocialClimb / RLDatix: The company was acquired by RLDatix, via its financial sponsors Nordic Capital, Pantheon International, Torreal, Resolve Growth Partners, Susquehanna Growth Equity, TA Associates Management, and Five Arrows Principal Investments through an LBO on September 18, 2024 for an undisclosed amount. The company is a developer of a comprehensive, HIPAA-compliant healthcare marketing platform.

Vapotherm / Perceptive Advisors: The company was acquired by Perceptive Advisors and SLR Capital Partners through a public-to-private LBO on September 20, 2024 for an undisclosed amount. Vapotherm Inc is a medical technology business focused on non-invasive respiratory support.